PMV Pharmaceuticals (PMVP) Stock Analysis

What PMV Pharmaceuticals does

PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.

Key metrics

ETFs linked to PMVP

Broad-market and Healthcare sector ETFs an investor holding PMV Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PMVP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for PMV Pharmaceuticals?

PMV Pharmaceuticals trades under the ticker PMVP on NASDAQ.

Which exchange is PMVP listed on?

PMVP is listed on NASDAQ.

What sector does PMV Pharmaceuticals operate in?

PMV Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PMVP in a portfolio?

PortView shows PMVP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.